Teva Pharmaceutical's AJOVY® is Proven to be Effective in Children with Migraine

GuruFocus

2024-12-06

AJOVY® (fremanezumab) was first aimed to prevent episodic migraine in adults and Teva Pharmaceutical (TEVA, Financial) wonders if the same drug gives effective results to children with migraine.

And Teva just recently announced positive results from its Phase 3 SPACE (an acronym for Study of Preventive Ajovy in Children and Adolescents) evaluating AJOVY® for the prevention of episodic migraine in children and adolescents aged 6-17 years.

The trial demonstrated statistically significant superior efficacy compared to placebo over 12 weeks, with a favorable safety profile consistent with that observed in adults.

The study included 237 children who had been diagnosed with migraine for at least six months, with fewer than 14 headache days per month. Highlights from the data showed that fremanezumab achieved a significant reduction in monthly migraine days and monthly headache days compared to placebo2. Additionally, a higher number of children achieved a 50% response rate with fremanezumab compared to placebo.

This brings hopes to treat young patients who live with migraine, a condition with limited treatment choices for kids.

Make more informed investment decision now by visiting GuruFocus and deep dive into TEVA' performance with charts, insiders, political positions, guru insights and more!

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2489744230"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489744230\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2489744230?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489744230","market":"hk","top_or_hot":-1,"title":"Teva Pharmaceutical's AJOVY® is Proven to be Effective in Children with Migraine","media":"GuruFocus","content":"<html><body><div><div><p>AJOVY® (fremanezumab) was first aimed to prevent episodic migraine in adults and Teva Pharmaceutical (TEVA, Financial) wonders if the same drug gives effective results to children with migraine.</p><p>And Teva just recently announced positive results from its Phase 3 SPACE (an acronym for Study of Preventive Ajovy in Children and Adolescents) evaluating AJOVY® for the prevention of episodic migraine in children and adolescents aged 6-17 years. </p><p>The trial demonstrated statistically significant superior efficacy compared to placebo over 12 weeks, with a favorable safety profile consistent with that observed in adults.</p><p>The study included 237 children who had been diagnosed with migraine for at least six months, with fewer than 14 headache days per month. Highlights from the data showed that fremanezumab achieved a significant reduction in monthly migraine days and monthly headache days compared to placebo2. Additionally, a higher number of children achieved a 50% response rate with fremanezumab compared to placebo.</p><p>This brings hopes to treat young patients who live with migraine, a condition with limited treatment choices for kids. </p><p><span>Make more informed investment decision now by visiting GuruFocus and deep dive into </span>TEVA<span>' performance with charts, insiders, political positions, guru insights and more!</span></p></div></div></body></html>","source":"gurufocus_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical's AJOVY® is Proven to be Effective in Children with Migraine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical's AJOVY® is Proven to be Effective in Children with Migraine\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GuruFocus</strong><span class=\"h-time small\">2024-12-06 22:20</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div><div><p>AJOVY® (fremanezumab) was first aimed to prevent episodic migraine in adults and Teva Pharmaceutical (TEVA, Financial) wonders if the same drug gives effective results to children with migraine.</p><p>And Teva just recently announced positive results from its Phase 3 SPACE (an acronym for Study of Preventive Ajovy in Children and Adolescents) evaluating AJOVY® for the prevention of episodic migraine in children and adolescents aged 6-17 years. </p><p>The trial demonstrated statistically significant superior efficacy compared to placebo over 12 weeks, with a favorable safety profile consistent with that observed in adults.</p><p>The study included 237 children who had been diagnosed with migraine for at least six months, with fewer than 14 headache days per month. Highlights from the data showed that fremanezumab achieved a significant reduction in monthly migraine days and monthly headache days compared to placebo2. Additionally, a higher number of children achieved a 50% response rate with fremanezumab compared to placebo.</p><p>This brings hopes to treat young patients who live with migraine, a condition with limited treatment choices for kids. </p><p><span>Make more informed investment decision now by visiting GuruFocus and deep dive into </span>TEVA<span>' performance with charts, insiders, political positions, guru insights and more!</span></p></div></div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.gurufocus.com/news/2625887/teva-pharmaceuticals-ajovy-is-proven-to-be-effective-in-children-with-migraine\">GuruFocus</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦製藥","start_time":0,"source_url":"https://www.gurufocus.com/news/2625887/teva-pharmaceuticals-ajovy-is-proven-to-be-effective-in-children-with-migraine","article_id":"2489744230","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489744230","pubTimestamp":1733494855,"columns":[],"sourceInfo":{"source_id":"gurufocus_highlight","name":"GuruFocus"},"weMediaInfo":null,"summary":"AJOVY  was first aimed to prevent episodic migraine in adults and Teva Pharmaceutical  wonders if the same drug gives effective results to children with migraine.And Teva just recently announced positive results from its Phase 3 SPACE  evaluating AJOVY for the prevention of episodic migraine in children and adolescents aged 6-17 years. The trial demonstrated statistically significant superior efficacy compared to placebo over 12 weeks, with a favorable safety profile consistent with that observed in adults.The study included 237 children who had been diagnosed with migraine for at least six months, with fewer than 14 headache days per month. Highlights from the data showed that fremanezumab achieved a significant reduction in monthly migraine days and monthly headache days compared to placebo2. Additionally, a higher number of children achieved a 50% response rate with fremanezumab compared to placebo.This brings hopes to treat young patients who live with migraine, a condition with li","collect":0,"end_time":0,"defaultTopTitle":"gurufocus.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"梯瓦制药的AJOVY®被证明对儿童偏头痛有效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"AJOVY® (fremanezumab) was first aimed to prevent episodic migraine in adults and Teva Pharmaceutical (TEVA, Financial) wonders if the same drug gives effective results to children with migraine.And Teva just recently announced positive results from its Phase 3 SPACE (an acronym for Study of Preventive Ajovy in Children and Adolescents) evaluating AJOVY® for the prevention of episodic migraine in children and adolescents aged 6-17 years. The trial demonstrated statistically significant superior efficacy compared to placebo over 12 weeks, with a favorable safety profile consistent with that observed in adults.The study included 237 children who had been diagnosed with migraine for at least six months, with fewer than 14 headache days per month. Highlights from the data showed that fremanezumab achieved a significant reduction in monthly migraine days and monthly headache days compared to placebo2. Additionally, a higher number of children achieved a 50% response rate with fremanezumab compared to placebo.This brings hopes to treat young patients who live with migraine, a condition with limited treatment choices for kids. Make more informed investment decision now by visiting GuruFocus and deep dive into TEVA' performance with charts, insiders, political positions, guru insights and more!","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}